Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Failure of the addition of methylprednisolone to intermediate-dose cyclophosphamide and lenograstim for stem cell mobilization to make the timing of PBSC harvesting more predictable

Bone Marrow Transplantation volume 40, pages 293–294 (2007)Cite this article

Observing that the etoposide, methylprednisolone, cytarabine and cisplatin (ESHAP) regimen produced predictable stem cell harvests1 but recognizing that it was not suited for several patient groups, we investigated whether the addition of methylprednisolone 500 mg o.d. p.o. days 1–4 to our standard mobilization regimen comprising intermediate-dose cyclophosphamide 1.5 g/m2 and G-CSF (lenograstim 150 μg/m2 o.d. s.c. from day 5 until completion of harvesting) was able to achieve at least 80% of mobilization attempts resulting in the first day of harvesting falling on the same day after the beginning of mobilization, no patients mobilizing earlier without also having more than 2 × 106/kg CD34+ cells harvested on that same day and in no patients the harvesting needing to be deferred to the third day (hypothetical ideal patient cohort, Figure 1b).

The primary study end point was the day post-mobilization on which the first leukapheresis was carried out. Secondary end points were tolerability, harvest yield and the number of harvests required to achieve the desired harvest yield. The study protocol was registered under EudraCT number 2005-002247-86 and approved by Sunderland Research Ethics Committee.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Watts MJ, Ings SJ, Leverett D, MacMillan A, Devereux S, Goldstone AH et al. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(−2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients. Br J Cancer 2000; 82: 278–282.

    Article  CAS  Google Scholar 

  2. Karanth M, Chakrabarti S, Lovell RA, Harvey C, Holder K, McConkey CC et al. A randomised study comparing peripheral blood progenitor mobilisation using intermediate-dose cyclophosphamide plus lenograstim with lenograstim alone. Bone Marrow Transplant 2004; 34: 399–403.

    Article  CAS  Google Scholar 

  3. Bargetzi MJ, Passweg J, Bärtschi E, Schönenberger A, Gwerder C, Tichelli A et al. Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective. Bone Marrow Transplant 2003; 31: 99–103.

    Article  CAS  Google Scholar 

  4. Holtan SG, Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB et al. Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma. Br J Haematol 2006; 133: 628–633.

    Article  CAS  Google Scholar 

  5. Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001; 98: 579–585.

    Article  CAS  Google Scholar 

  6. Condomines M, Quittet P, Lu Z-Y, Nadal L, Latry P, Lopez E et al. Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor. J Immunol 2006; 176: 6631–6639.

    Article  CAS  Google Scholar 

  7. Furtado M, Jones C, Coleman J, Brown R, Walton S, Rudin C . PBSC mobilisation with G-CSF alone as opposed to mobilisation with chemotherapy and G-CSF produces higher lymphocyte yields followed by faster lymphocyte recovery after high dose melphalan chemotherapy and autologous haemopoietic rescue in myeloma patients. Br J Haematol 2007; 137 (Suppl 1): abstract 108.

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Royal Devon & Exeter Hospital, Wonford, Exeter, UK

    C E Rudin

  2. Departments of Research and Development, Royal Devon & Exeter Hospital, Wonford, Exeter, UK

    J Melhuish & J Hall

Authors
  1. C E Rudin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Melhuish
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Hall
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C E Rudin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rudin, C., Melhuish, J. & Hall, J. Failure of the addition of methylprednisolone to intermediate-dose cyclophosphamide and lenograstim for stem cell mobilization to make the timing of PBSC harvesting more predictable. Bone Marrow Transplant 40, 293–294 (2007). https://doi.org/10.1038/sj.bmt.1705717

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705717

Search

Advanced search

Quick links